Zacks Investment Research
17 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
CRISPR Therapeutics AG is projected to report a 733.26% year-over-year increase in quarterly revenue to $7.42 million. — Hyper-growth in revenue typically signals strong commercial adoption or milestone achievements, which is a primary driver for biotech valuations.
+0.60The company is expected to report an annual revenue increase of 722.82% to $28.88 million. — Sustained annual growth expectations provide a positive long-term outlook for the company's scaling capabilities.
+0.50CRISPR Therapeutics shares have fallen 10.21% over the past month, underperforming both the Medical sector (5.37%) and the S&P 500 (0.32%). — Significant relative underperformance suggests negative sentiment or specific company headwinds despite broader sector strength.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The Zacks Consensus EPS estimate for the company has decreased by 0.26% over the last month. — A downward revision in earnings estimates, even if slight, typically correlates with a negative effect on near-term stock price.
-0.20CRISPR Therapeutics AG currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a neutral outlook, indicating no strong immediate catalyst for price movement from a ranking perspective.
+0.00Which stocks this story touches
The stock price has depreciated over the past month and recently closed lower than the previous day.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
